Clinical Trials in Cleveland

Showing 6001-6020 of 19,775 trials

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

NCT04538352

This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple daily injections of insulin (MDI), in patients with T2D with adequate glycemic control (≤ 7.5%) on MDI-based regimens (≤ 80 units of insulin per day), vs. further titration of insulin therapy in those continuing MDI. Weight loss, hypoglycemic episodes, and improvement in diabetes-treatment satisfaction will also be assessed between the two groups.

Type 2 Diabetes

The Cleveland Clinic60 participantsStarted Jan 2021

Cleveland, Ohio, United States

COMPLETEDPhase 2< 1 mile

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

NCT01894061

NovoTTF-100A is a device and Bevacizumab is a study drug that have both been approved by the FDA (Food and Drug Administration) for use as monotherapy in treating glioblastoma multiforme. The NovoTTF-l00A is a portable battery operated device which produces TTFields within the human body using surface electrodes (transducer arrays). Intermediate frequency electric fields (TTFields) stunt the growth of tumor cells. The purpose of this study is to determine the efficacy of the combination of Bevacizumab and NovoTTF-100A in Bevacizumab naive (meaning have never received bevacizumab before) patients with recurrent glioblastoma (GBM) as measured by 6-month progression free survival.

Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma+1 more

Case Comprehensive Cancer Center25 participantsStarted Sep 2013

Cincinnati, Ohio, United States • Cleveland, Ohio, United States • Cleveland, Ohio, United States

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

Find Trials by Condition in Cleveland

Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM

Study Evaluating the Safety of Myeliviz Myelin-Targeting PET Agent

A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

Using Calcium Hydroxylapatite To Treat Gum Recession and Tooth Hypersensitivity

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

INFINITY™Total Ankle Replacement Follow-up

Neuroblastoma Precision Trial

A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007

Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome

Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception

A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

MCT for the Harvard/UCSF ROBIN Center